Use of DPP4 inhibitors in Italy does not correlate with diabetes prevalence among COVID-19 deaths.


Journal

Diabetes research and clinical practice
ISSN: 1872-8227
Titre abrégé: Diabetes Res Clin Pract
Pays: Ireland
ID NLM: 8508335

Informations de publication

Date de publication:
Jan 2021
Historique:
received: 24 07 2020
revised: 22 08 2020
accepted: 04 09 2020
pubmed: 19 9 2020
medline: 16 2 2021
entrez: 18 9 2020
Statut: ppublish

Résumé

In a nationwide study of 3818 charts from patients with fatal COVID-19, we found that geographical differences in Dipeptidyl peptidase 4 (DPP4) inhibitors use did not correlate with diabetes prevalence among COVID-19 deaths, thus not supporting the hypothesis of a clinically relevant involvement of DPP4 inhibition in COVID-19 development and progression.

Identifiants

pubmed: 32946854
pii: S0168-8227(20)30697-5
doi: 10.1016/j.diabres.2020.108444
pmc: PMC7492144
pii:
doi:

Substances chimiques

Dipeptidyl-Peptidase IV Inhibitors 0
DPP4 protein, human EC 3.4.14.5
Dipeptidyl Peptidase 4 EC 3.4.14.5

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

108444

Informations de copyright

Copyright © 2020 Elsevier B.V. All rights reserved.

Déclaration de conflit d'intérêts

Conflict of interests RS, MD and CP have no conflict of interest to declare for the preparation of this manuscript. EM has received speaker fees from Astra-Zeneca and Lilly and research grants from scientific societies with the unrestricted support from AstraZeneca. PP has received speaker fees from AstraZeneca, MSD and Lilly. RB has received speaker fees from AstraZeneca, MSD and Lilly

Références

J Clin Invest. 2020 May 1;130(5):2620-2629
pubmed: 32217835
Lancet Respir Med. 2020 Apr;8(4):420-422
pubmed: 32085846
Am J Physiol Lung Cell Mol Physiol. 2018 Nov 1;315(5):L834-L845
pubmed: 30188745
Emerg Microbes Infect. 2020 Dec;9(1):601-604
pubmed: 32178593
Diabetologia. 2020 Aug;63(8):1500-1515
pubmed: 32472191
Eur J Pharm Sci. 2017 Mar 30;100:17-24
pubmed: 28065853
J Immunol. 2001 Feb 1;166(3):2041-8
pubmed: 11160254
Diabetes Obes Metab. 2020 Oct;22(10):1946-1950
pubmed: 32463179
Clin Exp Immunol. 2016 Jul;185(1):1-21
pubmed: 26919392
J Diabetes Complications. 2017 Sep;31(9):1458-1464
pubmed: 28647512

Auteurs

Rocky Strollo (R)

Department of Medicine, Unit of Endocrinology & Diabetes, Campus Bio-Medico University of Rome, Italy.

Ernesto Maddaloni (E)

Department of Experimental Medicine, Sapienza University of Rome, Italy.

Marco Dauriz (M)

Department of Internal Medicine, Section of Endocrinology and Diabetes, South-Tyrolean Healthcare System, Bolzano General Hospital, Bolzano, Italy.

Claudio Pedone (C)

Department of Medicine, Unit of Geriatrics, Campus Bio-Medico University of Rome, Italy.

Raffaella Buzzetti (R)

Department of Experimental Medicine, Sapienza University of Rome, Italy.

Paolo Pozzilli (P)

Department of Medicine, Unit of Endocrinology & Diabetes, Campus Bio-Medico University of Rome, Italy. Electronic address: p.pozzilli@unicampus.it.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH